人小细胞肺癌SH77多药耐药细胞系的建立及其生物学特征分析

Establishment of human small cell lung cancer SH77 multidrug resistance cell line and analysis of its biological properties

目的 建立人小细胞肺癌SH77/CDDPMDR细胞株并检测其生物学特性。方法 应用肺癌化疗的一线药物顺铂采用逐步增加剂量的方法诱导人SCLC细胞系SH77,建立MDR细胞系SH77/CDDP ;检测耐药细胞及其亲代细胞对 7种化疗药物的敏感性 ;观察细胞形态和超微结构 ;测定细胞生长曲线和细胞周期。结果 在国内首次成功建立了SCLCMDR细胞系SH77/CDDP ,药敏结果显示该细胞对 7种化疗药物有不同程度的抗药性 ;耐药细胞较其亲代略增大 ,核浆比例减小 ,线粒体、高尔基体、粗面内质网和游离核糖体增多 ,细胞表面指状突起明显 ;耐药细胞与其亲代细胞增殖速度接近 ;其S期细胞增多 (P <0 .0 5 ) ,提示耐药细胞DNA合成增加。结论 SH77/CDDP是可靠的人SCLCMDR细胞模型 ,SH77/CD

Objective To establish a small cell lung cancer (SCLC) multidrug resistance (MDR) cell line SH77/CDDP and analyze its biological properties. Methods The SCLC MDR cell line SH77/CDDP was established by increasing gradually the dose of cisplatin, the first line chemotherapeutic drug for lung cancer. The chemosensitivities of SH77/CDDP and its parental cell line to 7 chemotherapeutic drugs were tested. Changes in cellular morphology and ultrastructure were observed. The cell growth curve and cell cycle were also determined. Results SCLC MDR cell line SH77/CDDP having different drug resistance to the 7 chemotherapeutic drugs was established successfully. Compared with that of its parental cell, the size of MDR cell was a bit bigger. The ratio of nucleus to cell plasma decreased and mitochondria, Golgi bodies, rough endoplasmic reticulums and free ribosomes increased. The finger like apophysis was obvious. The rate of cell proliferation of SH77/CDDP was similar to that of SH77, but the number of cells in S phase increased( P <0.05), suggesting that the DNA synthesis was increased in MDR cell line. Conclusion SH77/CDDP is a reliable MDR cell model of human SCLC. The establishment of this cell line has laid basis for further study of the mechanism of human SCLC MDR induced by cisplatin.